MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Zomedica Corp. Deferred Revenue 2011-2026 | ZOM
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Zomedica Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 368 K | 331 K | 276 K | 207 K | 198 K | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 368 K | 198 K | 276 K |
Quarterly Deferred Revenue Zomedica Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 353 K | 330 K | 319 K | 331 K | 293 K | 271 K | - | 276 K | 257 K | 255 K | 242 K | 207 K | 205 K | 153 K | 148 K | 198 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 353 K | 148 K | 256 K |
Deferred Revenue of other stocks in the Drug manufacturers industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
49 K | - | 7.5 % | $ 6.35 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
27.8 K | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
85.4 M | - | - | $ 754 M | USA |
 |
Assertio Holdings
ASRT
|
200 K | $ 18.95 | -1.61 % | $ 121 M | USA |
 |
Athenex
ATNX
|
2.82 M | - | -23.39 % | $ 1.76 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
207 K | $ 3.07 | -0.97 % | $ 43.2 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
114 K | - | - | $ 2.06 B |  France |
 |
HEXO Corp.
HEXO
|
8.21 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Bausch Health Companies
BHC
|
26 M | $ 5.24 | -3.23 % | $ 1.91 B | Canada |
 |
Aurora Cannabis
ACB
|
27 M | $ 3.36 | -2.32 % | $ 86.3 M | Canada |
 |
Harrow Health
HROW
|
788 K | $ 34.58 | -1.57 % | $ 1.27 B | USA |
 |
Catalent
CTLT
|
250 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
545 K | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
6 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
600 K | - | - | $ 28.9 M |  Irlanda |
 |
Evolus
EOLS
|
11.5 M | $ 3.98 | -4.45 % | $ 257 M | USA |
 |
Emergent BioSolutions
EBS
|
27.2 M | $ 7.78 | -3.95 % | $ 398 M | USA |
 |
Pacira BioSciences
PCRX
|
102 K | $ 22.33 | 0.25 % | $ 1.03 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
641 K | $ 2.22 | -4.52 % | $ 2.76 M | USA |
 |
Tilray
TLRY
|
23.7 M | $ 6.49 | -2.63 % | $ 4.01 B | Canada |
 |
Veru
VERU
|
400 K | $ 2.45 | 1.92 % | $ 330 M | USA |
 |
OptiNose
OPTN
|
160 K | - | - | $ 1.08 B | USA |
 |
ProPhase Labs
PRPH
|
2.5 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
1 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
543 K | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
503 K | $ 0.7 | -4.12 % | $ 3.02 M | USA |
 |
Rockwell Medical
RMTI
|
46 K | $ 0.95 | -1.55 % | $ 34.2 M | USA |
 |
SCYNEXIS
SCYX
|
235 K | $ 0.96 | 5.21 % | $ 47.9 M | USA |
 |
Solid Biosciences
SLDB
|
10.4 M | $ 7.47 | -3.49 % | $ 654 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
172 K | - | - | $ 55.5 M | USA |
 |
China Pharma Holdings
CPHI
|
112 K | $ 0.61 | - | $ 2.62 M |  China |
 |
TherapeuticsMD
TXMD
|
523 K | $ 2.02 | -8.18 % | $ 23.4 M | USA |